# A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

> **NCT03138512** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1641 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** ipilimumab
- **DRUG:** nivolumab placebo
- **DRUG:** ipilimumab placebo

## Key facts

- **NCT ID:** NCT03138512
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-07
- **Primary completion:** 2023-09-28
- **Final completion:** 2024-02-01
- **Target enrollment:** 1641 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138512, "A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03138512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*